AstraZeneca vaccine found to be 79% effective in U.S. trial, ‘no increased risk’ of blood clots The safety and efficacy analysis of the vaccine was based on 32,449 participants in a phase 3 trial. The results come shortly after several countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people. AstraZeneca said an independent data safety monitoring board identified no safety concerns related to the shot.[출처] [외신이 본 코로나] 아스트라제네카 코로나 백신, 미국 임상시험에서 효과 79%|작성자 디스클로저
[외신이 본 코로나] 아스트라제네카 코로나 백신, 미국 임상시험에서 효과 79%
The safety and efficacy analysis of the vaccine was based on 32,449 participants in a phase 3 trial.
The results come shortly after several countries temporarily suspended use of the shot following reports of blood clots in some vaccinated people.
AstraZeneca said an independent data safety monitoring board identified no safety concerns related to the shot.[출처] [외신이 본 코로나] 아스트라제네카 코로나 백신, 미국 임상시험에서 효과 79%|작성자 디스클로저